Jennifer A Sinnott1, Katherine Brumberg2, Kathryn M Wilson3, Ericka M Ebot4, Edward L Giovannucci5, Lorelei A Mucci3, Jennifer R Rider6. 1. Department of Statistics, The Ohio State University, Columbus, OH, USA; Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA. 2. Yale University, New Haven, CT, USA. 3. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA; Channing Division of Network Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA. 4. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA. 5. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA; Channing Division of Network Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA; Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA, USA. 6. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA; Department of Epidemiology, Boston University School of Public Health, Boston, MA, USA. Electronic address: rider@bu.edu.
Abstract
In a prospective study of 31 925 men with 18 yr of follow-up, higher ejaculation frequency (EF) throughout adulthood was associated with lower rates of prostate cancer. To further explore this association, we evaluated whole transcriptome gene expression in the prostate tissue from study participants who developed prostate cancer between 1992 and 2004 (n=157 tumor tissue, n=85 adjacent normal). We tested for trends in gene expression according to the level of EF as self-reported in 1992 for ages 20-29 yr, 40-49 yr, and the year prior to the questionnaire, 1991. There were no associations between EF and gene expression in areas of tumor after accounting for multiple testing. In contrast, in the adjacent normal tissue, 409 genes and six pathways were differentially expressed at a false discovery rate ≤0.2 across categories of EF in 1991. These results suggest that ejaculation affects the expression of genes in the normal prostate tissue. The identified genes and pathways provide potential biological links between EF and prostate tumorigenesis. PATIENT SUMMARY: To explore previous findings that men who ejaculate more frequently have lower risk of prostate cancer, we evaluated molecular alterations in the prostate tissue according to each man's frequency of ejaculation prior to diagnosis. We identified biological processes that could link ejaculation frequency and prostate cancer.
In a prospective study of 31 925 men with 18 yr of follow-up, higher ejaculation frequency (EF) throughout adulthood was associated with lower rates of prostate cancer. To further explore this association, we evaluated whole transcriptome gene expression in the prostate tissue from study participants who developed prostate cancer between 1992 and 2004 (n=157 tumor tissue, n=85 adjacent normal). We tested for trends in gene expression according to the level of EF as self-reported in 1992 for ages 20-29 yr, 40-49 yr, and the year prior to the questionnaire, 1991. There were no associations between EF and gene expression in areas of tumor after accounting for multiple testing. In contrast, in the adjacent normal tissue, 409 genes and six pathways were differentially expressed at a false discovery rate ≤0.2 across categories of EF in 1991. These results suggest that ejaculation affects the expression of genes in the normal prostate tissue. The identified genes and pathways provide potential biological links between EF and prostate tumorigenesis. PATIENT SUMMARY: To explore previous findings that men who ejaculate more frequently have lower risk of prostate cancer, we evaluated molecular alterations in the prostate tissue according to each man's frequency of ejaculation prior to diagnosis. We identified biological processes that could link ejaculation frequency and prostate cancer.
Authors: Svitlana Tyekucheva; Neil E Martin; Edward C Stack; Wei Wei; Vinod Vathipadiekal; Levi Waldron; Michelangelo Fiorentino; Rosina T Lis; Meir J Stampfer; Massimo Loda; Giovanni Parmigiani; Lorelei A Mucci; Michael Birrer Journal: J Mol Diagn Date: 2015-04-30 Impact factor: 5.568
Authors: Aravind Subramanian; Pablo Tamayo; Vamsi K Mootha; Sayan Mukherjee; Benjamin L Ebert; Michael A Gillette; Amanda Paulovich; Scott L Pomeroy; Todd R Golub; Eric S Lander; Jill P Mesirov Journal: Proc Natl Acad Sci U S A Date: 2005-09-30 Impact factor: 11.205
Authors: Kathryn L Penney; Jennifer A Sinnott; Svitlana Tyekucheva; Travis Gerke; Irene M Shui; Peter Kraft; Howard D Sesso; Matthew L Freedman; Massimo Loda; Lorelei A Mucci; Meir J Stampfer Journal: Cancer Epidemiol Biomarkers Prev Date: 2014-11-04 Impact factor: 4.254
Authors: Kathryn L Penney; Jennifer A Sinnott; Katja Fall; Yudi Pawitan; Yujin Hoshida; Peter Kraft; Jennifer R Stark; Michelangelo Fiorentino; Sven Perner; Stephen Finn; Stefano Calza; Richard Flavin; Matthew L Freedman; Sunita Setlur; Howard D Sesso; Swen-Olof Andersson; Neil Martin; Philip W Kantoff; Jan-Erik Johansson; Hans-Olov Adami; Mark A Rubin; Massimo Loda; Todd R Golub; Ove Andrén; Meir J Stampfer; Lorelei A Mucci Journal: J Clin Oncol Date: 2011-05-02 Impact factor: 44.544
Authors: Jennifer R Rider; Kathryn M Wilson; Jennifer A Sinnott; Rachel S Kelly; Lorelei A Mucci; Edward L Giovannucci Journal: Eur Urol Date: 2016-03-28 Impact factor: 20.096
Authors: Michael F Leitzmann; Elizabeth A Platz; Meir J Stampfer; Walter C Willett; Edward Giovannucci Journal: JAMA Date: 2004-04-07 Impact factor: 56.272
Authors: Uma R Chandran; Rajiv Dhir; Changqing Ma; George Michalopoulos; Michael Becich; John Gilbertson Journal: BMC Cancer Date: 2005-05-13 Impact factor: 4.430
Authors: Cristina Magi-Galluzzi; Tara Maddala; Sara Moscovita Falzarano; Diana B Cherbavaz; Nan Zhang; Dejan Knezevic; Phillip G Febbo; Mark Lee; Hugh Jeffrey Lawrence; Eric A Klein Journal: Oncotarget Date: 2016-06-07